Luspatercept-aamt

Class: Hematopoietic Agents
Chemical Name: Activin receptor type IIB (synthetic human extracellular domain 107-amino acid fragment) fusion protein with glycylglycylglycine fusion protein with immunoglobulin G1 (synthetic human Fc region 225-amino acid C-terminal fragment), dimer
Molecular Formula: C₃₃₅₀H₅₀₇₀N₉₀₆O₁₀₄₄S₃₈
CAS Number: 1373715-00-4
Brands: Reblozyl

Medically reviewed by Drugs.com on Nov 29, 2021. Written by ASHP.

Introduction

Luspatercept-aamt is a hematopoietic agent.

Uses for Luspatercept-aamt

Luspatercept-aamt has the following uses:

Luspatercept-aamt is an erythroid maturation agent indicated for the treatment of anemia in adults with beta thalassemia who require regular red blood cell (RBC) transfusions.

Luspatercept-aamt has the following limitations of use:

Luspatercept-aamt is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

Luspatercept-aamt Dosage and Administration

General

Luspatercept-aamt is available in the following dosage form(s) and strength(s):

• For injection: 25 mg as lyophilized powder in a single-dose vial for reconstitution.

• For injection: 75 mg as lyophilized powder in a single-dose vial for reconstitution.

Dosage

It isessentialthat the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:

Adults

Dosage and Administration

• The recommended starting dose is 1 mg/kg once every 3 weeks by subcutaneous injection.

• Review hemoglobin (Hgb) results prior to each administration.

• See full prescribing information for preparation and administration instructions.

Cautions for Luspatercept-aamt

Contraindications

None.

Warnings/Precautions

Thrombosis/Thromboembolism

In adult patients with beta thalassemia, thromboembolic events (TEE) were reported in 8/223 (3.6%) luspatercept-aamt-treated patients. Reported TEEs included deep vein thromboses, pulmonary embolus, portal vein thrombosis, and ischemic strokes. Patients with known risk factors for thromboembolism (e.g., splenectomy or concomitant use of hormone replacement therapy) may be at further increased risk of thromboembolic conditions.

Consider thromboprophylaxis in patients with beta thalassemia at increased risk of TEE. Monitor patients receiving luspatercept-aamt for signs and symptoms of thromboembolic events and ins...